Form 8-K - Current report:
SEC Accession No. 0001193125-22-071340
Filing Date
2022-03-10
Accepted
2022-03-10 08:15:35
Documents
14
Period of Report
2022-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d305993d8k.htm   iXBRL 8-K 24842
2 EX-99.1 d305993dex991.htm EX-99.1 61419
6 GRAPHIC g305993g90r41.jpg GRAPHIC 10696
  Complete submission text file 0001193125-22-071340.txt   224237

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rapt-20220310.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rapt-20220310_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rapt-20220310_pre.xml EX-101.PRE 11253
8 EXTRACTED XBRL INSTANCE DOCUMENT d305993d8k_htm.xml XML 3355
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38997 | Film No.: 22727500
SIC: 2834 Pharmaceutical Preparations